Rh(D) alloimmunization is a process in which the immune system of a Rh-negative (Rh−) woman begins to produce antibodies against Rh-positive (Rh+) fetal red blood cells. This occurs when maternal and fetal blood mix, and the maternal immune system recognizes Rh-positive fetal cells as foreign. This condition can lead to serious fetal complications, including hemolytic disease of the fetus and newborn (HDFN).
When does Rh incompatibility occur?
Rh incompatibility develops when a Rh-negative woman is carrying a Rh-positive fetus. This may occur if the child’s father has Rh-positive blood and the fetus inherits the Rh factor. During a first pregnancy, the risk of clinically significant Rh incompatibility is relatively low; however, placental injury, trauma, invasive procedures, or bleeding may allow fetal red blood cells to enter the maternal circulation, triggering the production of anti-D antibodies.
In subsequent pregnancies, these maternal antibodies may cross the placenta and attack Rh-positive fetal red blood cells, leading to hemolysis, fetal anemia, and other complications.
Rh incompatibility may result in the following complications for the fetus and the newborn:
- Hemolytic disease of the fetus and newborn (HDFN)
- Hypoxia. Destruction of red blood cells reduces oxygen delivery to fetal tissues, potentially impairing organ and system development.
- Hyperbilirubinemia. After birth, increased red blood cell breakdown may cause neonatal jaundice due to elevated bilirubin levels; without treatment, this can lead to bilirubin encephalopathy (kernicterus).
Fortunately, Rh(D) alloimmunization in Belarus can be effectively prevented using medications that inhibit maternal antibody production.
Administration of anti-D immunoglobulin (anti-D gamma globulin) is the primary method of preventing Rh(D) alloimmunization. Anti-D immunoglobulin neutralizes Rh-positive fetal red blood cells that have entered the maternal circulation, thereby preventing activation of the maternal immune response and subsequent antibody formation.
Anti-D immunoglobulin is administered to Rh-negative women in the following situations:
- At 28 weeks of gestation, if the father is Rh-positive.
- Within 72 hours after delivery, if the newborn is Rh-positive.
- After abortion, miscarriage, ectopic pregnancy, or invasive obstetric procedures.
Rh(D) alloimmunization is a serious condition that may lead to severe fetal complications. However, with modern diagnostic methods and preventive strategies, its consequences can be effectively minimized. Administration of anti-D immunoglobulin is a proven and effective approach to preventing Rh incompatibility and antibody formation, ensuring a safer course of pregnancy and the birth of a healthy child.
In Belarus, prevention and management of Rh incompatibility during pregnancy are subject to strict medical oversight. A well-organized system of care for Rh-negative pregnant women is in place, allowing risks to both mother and fetus to be minimized.
